How did NKTR's revenue and expenses shift in Q4 2024?
4/14/2025 03:29pm
Nektar Therapeutics (NKTR) experienced a significant increase in revenue, with a 23.76% rise in its stock price, while its cost of goods sold and R&D expenses also saw notable changes in Q4 2024:
|code|Ticker|Name|Date|Cost of Goods Sold|R&D Expenses|Total Revenue|market_code|
|---|---|---|---|---|---|---|---|
|NKTR|NKTR.O|Nektar Therapeutics|2024 Q1|8534000|2.7408E7|2.1639E7|186|
|NKTR|NKTR.O|Nektar Therapeutics|2024 Q2|9740000|2.9724E7|2.3489E7|186|
|NKTR|NKTR.O|Nektar Therapeutics|2024 Q3|4435000|3.5031E7|2.4124E7|186|
|NKTR|NKTR.O|Nektar Therapeutics|2024 Q4|7978000|2.8744E7|2.9175E7|186|